Supernus Pharmaceuticals, Inc.
SUPN
$32.33
$0.110.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 453.61M | 403.21M | 347.19M | 297.74M | 254.87M |
| Total Receivables | 142.08M | 145.41M | 152.49M | 147.73M | 144.16M |
| Inventory | 54.29M | 63.98M | 68.16M | 75.08M | 77.41M |
| Prepaid Expenses | 36.09M | 27.40M | 23.17M | 23.77M | 16.68M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 686.07M | 640.00M | 591.00M | 544.32M | 493.11M |
|
|
|||||
| Total Current Assets | 686.07M | 640.00M | 591.00M | 544.32M | 493.11M |
| Net Property, Plant & Equipment | 36.02M | 37.96M | 40.04M | 42.72M | 42.52M |
| Long-term Investments | 117.02M | 117.02M | 117.02M | 117.02M | 117.02M |
| Goodwill | 117.02M | 117.02M | 117.02M | 117.02M | 117.02M |
| Total Other Intangibles | 521.91M | 540.16M | 559.64M | 579.75M | 599.89M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 7.05M | 7.56M | 8.12M | 8.62M | 8.51M |
| Total Assets | 1.37B | 1.34B | 1.32B | 1.30B | 1.28B |
|
|
|||||
| Total Accounts Payable | 4.59M | 6.39M | 4.63M | 14.40M | 1.96M |
| Total Accrued Expenses | 180.21M | 171.88M | 184.88M | 170.55M | 166.26M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 6.89M | 9.23M | 9.68M | 9.13M | 8.33M |
| Total Finance Division Other Current Liabilities | 100.72M | 104.01M | 109.46M | 120.47M | 113.64M |
| Total Other Current Liabilities | 100.72M | 104.01M | 109.46M | 120.47M | 113.64M |
| Total Current Liabilities | 292.40M | 291.51M | 308.66M | 314.55M | 290.20M |
|
|
|||||
| Total Current Liabilities | 292.40M | 291.51M | 308.66M | 314.55M | 290.20M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 27.38M | 28.93M | 30.29M | 32.99M | 33.20M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 12.56M | 15.12M | 19.43M | 27.38M | 32.77M |
| Total Liabilities | 332.34M | 335.55M | 358.38M | 374.92M | 356.16M |
|
|
|||||
| Common Stock & APIC | 479.50M | 465.97M | 455.23M | 447.02M | 439.55M |
| Retained Earnings | 556.43M | 541.10M | 502.60M | 482.69M | 482.56M |
| Treasury Stock & Other | -189.00K | 78.00K | -372.00K | -534.00K | -593.00K |
| Total Common Equity | 1.04B | 1.01B | 957.45M | 929.17M | 921.52M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.04B | 1.01B | 957.45M | 929.17M | 921.52M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.04B | 1.01B | 957.45M | 929.17M | 921.52M |
|
|
|||||